References
- Kreitman RJ, Wilson WH, Bergeron K, . Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345:241–247.
- Dijoseph JF, Dougher MM, Armellino DC, . Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 2007;21:2240–2245.
- Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007;7:255–266.
- Tateno H, Li H, Schur MJ, . Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol Cell Biol 2007;27:5699–5710.
- Chen WC, Completo GC, Sigal DS, . In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood 2010;115:4778–4786.
- Collins BE, Blixt O, Han S, . High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J Immunol 2006;177:2994–3003.
- O'Reilly MK, Paulson JC. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci 2009;30:240–248.
- Blixt O, Han S, Liao L, . Sialoside analogue arrays for rapid identification of high affinity siglec ligands. J Am Chem Soc 2008;130:6680–6681.